A report argued that health systems are not fully ready for the next wave of GLP-1-centered care, even as regulators broaden indications beyond obesity into cardiovascular risk reduction, MASH, and sleep apnea. The piece says pharma must clear three hurdles: evidence beyond weight loss, long-term care infrastructure for multi-year treatment, and trust in a rapidly expanding market. The update emphasizes that payers still grapple with affordability, appropriate use, and long-term coverage, while primary care faces chronic metabolic management without the clinical backup used in earlier obesity-focused rollouts. For biotech professionals, the operational message is that success in GLP-1 franchises will depend on aligning clinical evidence, reimbursement strategy, and real-world delivery capabilities—not only trial outcomes.